



AMERICAN COLLEGE OF SURGEONS

Inspiring Quality:
Highest Standards, Better Outcomes

100+years

CQIP

Cancer Quality Improvement Program



Commission
on Cancer®

CQIP

Cancer Quality Improvement Program

Wayne HealthCare

6411400

Greenville, OH

NCDB

CQIP



Annual Report 2015

Table of Contents

[Slide #5: Cancer Program Administrative Reports](#)

[Slide #11: Quality Measure Reports](#)

[Slide #40: Surgical Volume and Unadjusted 30, 90 Day Mortality After Complex Operations](#)

[Slide #50: Survival Reports](#)

[Slide #65: Breast Cancer - Additional Reports](#)

[Slide #75: Colon Cancer - Additional Reports](#)

[Slide #83: Non-Small-Cell Lung Cancer \(NSCLC\) - Additional Reports](#)

[Slide #92: Prostate Cancer - Additional Reports](#)

[Slide #102: Melanoma of the Skin Cancer - Additional Reports](#)

[Slide #110: Commission on Cancer](#)



Cancer Quality Improvement Program (CQIP)

- A data-driven, process and outcomes-based cancer quality improvement initiative
- Confidentially reports to 1,500 individual CoC-accredited hospitals their data as entered in NCDB (including comparisons with national data from all CoC-accredited programs)
- PDF download provides information to support the reports, technical details, report creation, and scientific justification and references for quality measures
- 2015 release provides CoC-accredited facilities with data on:
 - Compliance with CoC-adopted quality measures
 - Volume data for complex surgical oncology operations with 30-day and 90 day mortality
 - Unadjusted and risk-adjusted survival data for selected cancer sites
 - Other clinical data and administrative data, which will be updated and expanded annually



CoC Recommendations on the use of the CQIP Report

- The CQIP report should be presented and discussed at the Cancer Committee meeting
 - Major findings relevant to the cancer program should be listed
 - Interventions for improvement of quality of cancer care should be recommended
- Cancer Committee Leadership should present the report, major findings and recommendations to hospital leadership, including, but not limited to, CEO, COO, CMO, CNO, and bodies such as the Medical Staff Executive Committee, the hospital Quality Committee, etc
- As part of the accreditation process, these processes will be reviewed.



Cancer Program Administration Reports

Cancer Program Volume

- Total Case Volume Over Time, 2009–2013 *
- Insurance Status (including national comparison)


Cancer Program In/Out Migration

- Total In/Out Migration, 2009-2013 - My Facility
- In/Out Migration by Insurance Status, 2013 - My Facility

* Some facilities may see “Cranial Nerves Other” as one of their top ten cancer sites for case volume in the 2015 report that did not appear in prior CQIP reports. Prior to 2015 submissions, some “Other Cranial” histologies and primary sites such as meninges were incorrectly suppressed, but were allowed in 2015. The histologies and primary sites that were added may be found in the CQIP documentation.



Cancer Program Total Case Volume, 2009 - 2013 My Facility



If Miscellaneous appears in your graph, note that this is a SEER-defined group. The exact primary sites and histologies included in this group may be found in the CQIP documentation


Cancer Program Total Case Volume, 2009 - 2013 My Facility

	2009	2010	2011	2012	2013
Breast	28	22	32	31	31
Prostate	20	15	14	21	26
Colon	10	16	17	13	21
Urinary Bladder	7	9	4	8	8
Rectum	10	10	6	1	8
Melanoma of the Skin	8	7	4	4	7
NHL - Nodal	2	1	5	9	6
Lung, Bronchus - Non-Small Cell Carcinoma	2	3	4	5	3
Esophagus	0	2	1	4	3
Cranial Nerves Other	0	1	0	3	3
All Other Sites	20	18	22	31	24
TOTAL	107	104	109	130	140

If Miscellaneous appears in your table, note that this is a SEER-defined group. The exact primary sites and histologies included in this group may be found in the CQIP documentation




Insurance Status, 2010 - 2013 - My Facility vs. All CoC




	2010 My Facility	2011 My Facility	2012 My Facility	2013 My Facility	2013 All CoC
Not Insured	3.8 % (n=4)	2.8 % (n=3)	3.8 % (n=5)	6.4 % (n=9)	3.5 % (n=44005)
Private/Managed	26.9 % (n=28)	24.8 % (n=27)	18.5 % (n=24)	21.4 % (n=30)	38.8 % (n=483282)
Medicaid	8.7 % (n=9)	8.3 % (n=9)	6.9 % (n=9)	3.6 % (n=5)	6.3 % (n=78116)
Medicare	54.8 % (n=57)	64.2 % (n=70)	70 % (n=91)	67.1 % (n=94)	46.4 % (n=576837)
Other Government	5.8 % (n=6)	0 % (n=0)	0.8 % (n=1)	0 % (n=0)	2.8 % (n=35372)
Insurance Status Unknown	0 % (n=0)	0 % (n=0)	0 % (n=0)	1.4 % (n=2)	2.1 % (n=26362)

Total In/Out Migration, 2009 - 2013 - My Facility



	2009	2010	2011	2012	2013
Diagnosed Here and Treated Elsewhere	22.4 % (n=24)	31.7 % (n=33)	39.4 % (n=43)	46.2 % (n=60)	33.6 % (n=47)
Diagnosed and Treated Here	66.4 % (n=71)	66.3 % (n=69)	54.1 % (n=59)	51.5 % (n=67)	55.7 % (n=78)
Diagnosed Elsewhere and Treated Here	11.2 % (n=12)	1.9 % (n=2)	6.4 % (n=7)	2.3 % (n=3)	10.7 % (n=15)

In/Out Migration by Insurance Status, 2013 - My Facility



	Not Insured	Private/Managed	Medicaid	Medicare	Other Government	Unknown
Diagnosed Here and Treated Elsewhere	0.7 % (n=1)	10 % (n=14)	0 % (n=0)	22.9 % (n=32)	0 % (n=0)	0 % (n=0)
Diagnosed and Treated Here	5 % (n=7)	10 % (n=14)	2.1 % (n=3)	37.9 % (n=53)	0 % (n=0)	0.7 % (n=1)
Diagnosed Elsewhere and Treated Here	0.7 % (n=1)	1.4 % (n=2)	1.4 % (n=2)	6.4 % (n=9)	0 % (n=0)	0.7 % (n=1)

Quality Measure Reports

Accountability Measure

- Considered the current standard of care based on clinical trial evidence Commission on Cancer Standard 4.4.

Quality Improvement Measure (QI)

- Demonstrates good practice based on consensus. Usually not based on clinical trial evidence. Commission on Cancer Standard 4.5 addresses compliance with quality improvement.

Surveillance Measure

- Used at the community, regional, and/or national level to monitor patterns and trends of care in order to guide policymaking and resource allocation.



Cancer Program Practice Profile (CP³R) Estimated Performance Rates

- Breast (6)
- Colon (2)
- Gastric (1)
- Ovary (1)
- Cervix (3)
- Endometrium (2)
- Non-Small Cell Lung (3)
- Rectum (1)

Extensive assessment and validation of the measures were performed using cancer registry data reported to the National Cancer Data Base (NCDB).

Disclaimer: All measures are designed to assess performance at the hospital or systems-level, and are not intended for application to individual physician performance.




Quality Measure Reports – Breast

- **BCSRT:** Breast radiation after breast conserving surgery (NQF 0219 – Accountability)
- **MAC:** Combination chemotherapy for hormone receptor negative breast cancer (NQF 0559 – Accountability)
- **HT:** Adjuvant hormonal therapy for hormone receptor positive breast cancer (NQF 0220 – Accountability)
- **BCS:** Breast conserving surgery rate (Surveillance)
- **MASRT:** Radiation therapy recommended or administered following mastectomy within 1 year of diagnosis for women with 4 or more positive regional lymph nodes (Accountability)
- **nBx:** Image or palpation-guided needle biopsy (core or FNA) is performed for the diagnosis of breast cancer (Quality Improvement)

NQF = National Quality Forum Endorsed Measure




BREAST, 2013, BCSRT: Breast radiation after breast conserving surgery (NQF 0219 - Accountability)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (CCP)	All CoC Programs
Performance Rate	100 %	93.9 %	93 %	94.7 %	90.2 %	91.5 %
Denominator	6	2524	9505	5366	5304	52944
95 % CI	(100.0,100.0)	(93.0,94.8)	(92.5,93.5)	(94.1,95.3)	(89.4,91.0)	(91.3,91.7)

Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer. (CP3R data as of 11/02/2015)


BREAST, 2013, MAC: Combination chemotherapy for hormone receptor negative breast cancer (NQF 0559 - Accountability)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (CCP)	All CoC Programs
Performance Rate	NA	91.5 %	92.6 %	93 %	90.7 %	92.3 %
Denominator	0	568	2204	1147	1184	12397
95 % CI	(0.0,0.0)	(89.2,93.8)	(91.5,93.7)	(91.5,94.5)	(89.0,92.4)	(91.8,92.8)

Combination chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or Stage II or III hormone receptor negative breast cancer. (CP3R data as of 11/02/2015)


BREAST, 2013, HT: Adjuvant hormonal therapy for hormone receptor positive breast cancer (NQF 0220 - Accountability)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (CCP)	All CoC Programs
Performance Rate	100 %	93.8 %	93 %	94.7 %	90.1 %	91.2 %
Denominator	14	3503	12879	7170	7579	74509
95 % CI	(100.0,100.0)	(93.0,94.6)	(92.6,93.4)	(94.2,95.2)	(89.4,90.8)	(91.0,91.4)

Tamoxifen or third generation Aromatase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or stage IB - III hormone receptor positive breast cancer. (CP3R data as of 11/02/2015)


BREAST, 2013, BCS: Breast conserving surgery rate (Surveillance)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (CCP)	All CoC Programs
Performance Rate	77.3 %	64.9 %	65.2 %	66.4 %	65.1 %	62.6 %
Denominator	22	5327	20749	11727	11491	120267
95 % CI	(59.8,94.8)	(63.6,66.2)	(64.6,65.8)	(65.5,67.3)	(64.2,66.0)	(62.3,62.9)

Breast conservation surgery rate for women with AJCC clinical stage 0, I, or II breast cancer. (CP3R data as of 11/02/2015)


BREAST, 2013, MASRT: Post-mastectomy radiation for women with 4 or more positive regional lymph nodes (Accountability)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (CCP)	All CoC Programs
Performance Rate	100 %	87.8 %	90.4 %	89.6 %	86.3 %	87.6 %
Denominator	1	329	1294	689	800	7473
95 % CI	(100.0,100.0)	(84.3,91.3)	(88.8,92.0)	(87.3,91.9)	(83.9,88.7)	(86.9,88.3)

Radiation therapy is recommended or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with ≥ 4 positive regional lymph nodes. (CP3R data as of 11/02/2015)

BREAST, 2013, nBx: Image or palpation-guided needle biopsy (core or FNA) is performed for the diagnosis of breast cancer (Quality Improvement)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (CCP)	All CoC Programs
Performance Rate	95.8 %	86.7 %	90.7 %	89.4 %	88.1 %	90.3 %
Denominator	24	6431	24633	13934	14190	126851
95 % CI	(87.8,100.0)	(85.9,87.5)	(90.3,91.1)	(88.9,89.9)	(87.6,88.6)	(90.1,90.5)

Image or palpation-guided needle biopsy (core or FNA) is performed to establish diagnosis of breast cancer. (CP3R data as of 11/02/2015)

Quality Measure Reports - Cervix


CBRRT: Use of brachytherapy in patients treated with primary radiation with curative intent in any stage of cervical cancer (Surveillance)

CERRT: Radiation therapy completed within 60 days of initiation of radiation among women diagnosed with any stage of cervical cancer (Surveillance)

CERCT: Chemotherapy administered to cervical cancer patients who received radiation for stages IB2-IV cancer (Group 1) or with positive pelvic nodes, positive surgical margin, and/or positive parametrium (Group 2) (Surveillance)



CERVIX, 2013, CBRRT: Brachytherapy in cervical cancer patients treated with primary radiation (Surveillance)




	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (CCP)	All CoC Programs
Performance Rate	NA	76.2 %	75.1 %	80.3 %	55.9 %	72.5 %
Denominator	NA	122	458	305	170	2855
95 % CI	NA	(68.6,83.8)	(71.1,79.1)	(75.8,84.8)	(48.4,63.4)	(70.9,74.1)

Use of brachytherapy in patients treated with primary radiation with curative intent in any stage of cervical cancer. (CP3R data as of 11/02/2015)




CERVIX, 2013, CERRT: Radiation therapy completed within 60 days among women diagnosed with cervical cancer (Surveillance)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (CCP)	All CoC Programs
Performance Rate	NA	81.4 %	80 %	79.2 %	75.7 %	79.7 %
Denominator	NA	118	430	284	185	2701
95 % CI	NA	(74.4,88.4)	(76.2,83.8)	(74.5,83.9)	(69.5,81.9)	(78.2,81.2)

Radiation therapy completed within 60 days of initiation of radiation among women diagnosed with any stage of cervical cancer. (CP3R data as of 11/02/2015)

CERVIX, 2013, CERCT: Chemotherapy for cervical cancer patients who received radiation (Surveillance)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (CCP)	All CoC Programs
Performance Rate	NA	92.2 %	90.6 %	87.2 %	87.8 %	88.2 %
Denominator	NA	154	596	366	255	3770
95 % CI	NA	(88.0,96.4)	(88.3,92.9)	(83.8,90.6)	(83.8,91.8)	(87.2,89.2)

Chemotherapy administered to cervical cancer patients who received radiation for stages IB2-IV cancer (Group 1) or with positive pelvic nodes, positive surgical margin, and/or positive parametrium (Group 2) (CP3R data as of 11/02/2015)


Quality Measure Reports - Colon

- **ACT:** Adjuvant chemotherapy for lymph node positive colon cancer (NQF 0223 – Accountability)
- **12RLN:** At least 12 lymph nodes are removed and examined as part of primary colon cancer resection (NQF 0225 – Quality Improvement)

NQF = National Quality Forum Endorsed Measure




COLON, 2013, ACT: Adjuvant chemotherapy for lymph node positive colon cancer (NQF 0223 - Accountability)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (CCP)	All CoC Programs
Performance Rate	100 %	91 %	91.8 %	91.7 %	88.9 %	89.3 %
Denominator	3	489	1710	965	1220	9718
95 % CI	(100.0,100.0)	(88.5,93.5)	(90.5,93.1)	(90.0,93.4)	(87.1,90.7)	(88.7,89.9)

Adjuvant chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer. (CP3R data as of 11/02/2015)

COLON, 2013, 12RL: At least 12 regional lymph nodes removed and pathologically examined for resected colon cancer (NQF 0225 - Quality Improvement)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (CCP)	All CoC Programs
Performance Rate	92.9 %	88.4 %	90.6 %	88.2 %	86 %	89.9 %
Denominator	14	2074	7455	4296	5156	40959
95 % CI	(79.4,100.0)	(87.0,89.8)	(89.9,91.3)	(87.2,89.2)	(85.1,86.9)	(89.6,90.2)


At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer. (CP3R data as of 11/02/2015)

Quality Measure Reports - Endometrium

- **ENDCTRT:** Chemotherapy and/or radiation administered to patients with Stage IIIC or IV Endometrial cancer (Surveillance)
- **ENDRLC:** Endoscopic, laparoscopic, or robotic surgery performed for all Endometrial cancer (Surveillance)




ENDOMETRIUM, 2013, ENDCTRT: Chemotherapy and/or radiation administered to patients with Endometrial cancer (Surveillance)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (CCP)	All CoC Programs
Performance Rate	NA	81.1 %	82.6 %	83.8 %	69.1 %	79.8 %
Denominator	0	90	384	240	55	2394
95 % CI	(0.0,0.0)	(73.0,89.2)	(78.8,86.4)	(79.1,88.5)	(56.9,81.3)	(78.2,81.4)

Chemotherapy and/or radiation recommended to patients with Stage IIIc or IV Endometrial cancer. (CP3R data as of 11/02/2015)

ENDOMETRIUM, 2013, ENDLRC: Endoscopic, laparoscopic, or robotic surgery performed for all Endometrial cancer (Surveillance)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (CCP)	All CoC Programs
Performance Rate	NA	58.7 %	68.3 %	65.4 %	53.4 %	72.3 %
Denominator	0	1089	4580	2748	939	26531
95 % CI	(0.0,0.0)	(55.8,61.6)	(67.0,69.6)	(63.6,67.2)	(50.2,56.6)	(71.8,72.8)


Endoscopic, laparoscopic, or robotic surgery performed for all Endometrial cancer (excluding sarcoma and lymphoma), for all stages except stage IV. (CP3R data as of 11/02/2015)

Quality Measure Reports - Gastric

- **G15RLN:** At least 15 regional lymph nodes are removed and pathologically examined for resected gastric cancer (Quality Improvement)



GASTRIC, 2013, G15RLN: At least 15 regional lymph nodes are removed and pathologically examined for resected gastric cancer (Quality Improvement)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (CCP)	All CoC Programs
Performance Rate	NA	54.1 %	53.2 %	50.5 %	41.8 %	54.3 %
Denominator	0	111	432	220	194	2846
95 % CI	(0.0,0.0)	(44.8,63.4)	(48.5,57.9)	(43.9,57.1)	(34.9,48.7)	(52.5,56.1)


At least 15 regional lymph nodes are removed and pathologically examined for resected gastric cancer. (CP3R data as of 11/02/2015)

Quality Measure Reports - Non-Small Cell Lung

- **10RLN:** At least 10 regional lymph nodes removed and pathologically examined for AJCC stage IA, IB, IIA, and IIB resected NSCLC (Surveillance)
- **LCT:** Systemic chemotherapy is administered or recommended within 4 months prior to surgery or within 6 months postoperatively for surgically resected cases with pathologic, lymph node-positive (pN1) and (pN2) NSCLC (Quality Improvement)
- **LNoSurg:** Surgery is not the first course of treatment for cN2, M0 cases (Quality Improvement)




NSCLC, 2013, 10RLN: At least 10 regional lymph nodes removed and pathologically examined for resected NSCLC (Surveillance)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (CCP)	All CoC Programs
Performance Rate	NA	37.7 %	39.3 %	47.5 %	28.9 %	41 %
Denominator	0	1012	3552	2215	1056	20055
95 % CI	(0.0,0.0)	(34.7,40.7)	(37.7,40.9)	(45.4,49.6)	(26.2,31.6)	(40.3,41.7)

At least 10 regional lymph nodes are removed and pathologically examined for AJCC stage IA, IB, IIA, and IIB resected NSCLC. (CP3R data as of 11/02/2015)


NSCLC, 2013, LCT: Systemic chemotherapy administered or recommended for pre or postoperatively resected NSCLC (Quality Improvement)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (CCP)	All CoC Programs
Performance Rate	NA	91 %	92.8 %	93.6 %	89.7 %	89.6 %
Denominator	0	188	766	451	330	4231
95 % CI	(0.0,0.0)	(86.9,95.1)	(91.0,94.6)	(91.3,95.9)	(86.4,93.0)	(88.7,90.5)

Systemic chemotherapy administered within 4 months to day preoperatively or day of surgery to 6 months postoperatively, or it is considered for surgically resected cases with pathologic, lymph node-positive (pN1) or (pN2) NSCLC.(CP3R data as of 11/02/2015)

NSCLC, LNoSurg: Surgery is not the first course of treatment for NSCLC (Quality Improvement)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (CCP)	All CoC Programs
Performance Rate	NA	90.7 %	91.8 %	91.1 %	92.2 %	92 %
Denominator	0	591	1947	1081	1126	9692
95 % CI	(0.0,0.0)	(88.4,93.0)	(90.6,93.0)	(89.4,92.8)	(90.6,93.8)	(91.5,92.5)


Surgery is not the first course of treatment for cN2, M0 cases. (CP3R data as of 11/02/2015)

Quality Measure Reports - Ovary

- **OVSAL:** Salpingo-oophorectomy with omentectomy, debulking; cytoreductive surgery, or pelvic exenteration in Stages I-IIIC Ovarian cancer (Surveillance)



OVARY, 2013, OVSAL: Salpingo-oophorectomy with omentectomy, debulking; cytoreductive surgery, or pelvic exenteration for Ovarian cancers (Surveillance)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (CCP)	All CoC Programs
Performance Rate	NA	70.4 %	69.6 %	69.5 %	50.7 %	70.5 %
Denominator	0	351	1410	802	211	8240
95 % CI	(0.0,0.0)	(65.6,75.2)	(67.2,72.0)	(66.3,72.7)	(44.0,57.4)	(69.5,71.5)


Salpingo-oophorectomy with omentectomy, debulking; cytoreductive surgery, or pelvic exenteration in Stages I-IIIc Ovarian cancer. (CP3R data as of 11/02/2015)

Quality Measure Reports - Rectum

- **RECRT:** Radiation therapy is administered as a component of therapy along with surgical resection (Surveillance)
- **RECRTCT:** Chemo and radiation therapy is administered or recommended for resected rectal cancers (Quality Improvement)



RECTUM, 2013, RECRTCT: Chemo and Radiation therapy is administered or recommended for resected rectal cancers (Quality Improvement)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (CCP)	All CoC Programs
Performance Rate	NA	86.7 %	87 %	89.4 %	84.4 %	86.3 %
Denominator	0	248	1067	566	482	5807
95 % CI	(0.0,0.0)	(82.5,90.9)	(85.0,89.0)	(86.9,91.9)	(81.2,87.6)	(85.4,87.2)


Preop CT & RT for clin AJCC T3N0, T4N0, or Stage III; or Postop CT & RT within 180 days of diagnosis for clin AJCC T1-2N0 with path AJCC T3N0, T4N0, or Stage III; or recommended; for patients < age 80 resected rectal cancer. (CP3R data as of 11/02/2015)

Breast Cancer—Additional Reports

- Stage Distribution
- In/Out Migration
- In/Out Migration by Insurance Status
- Insurance Status
- Distance Traveled
- First Course Treatment – Stage I
- Days to First Treatment: Cases Diagnosed and Treated at My Facility
- Days to First Treatment: Cases Diagnosed at My Facility or Elsewhere; Treated at My Facility
- Radiation Treatment After Breast Cancer Surgery Out Migration Heat Map By Zip Code




Stage Distribution - Breast Cancer Diagnosed in 2013, My Facility vs. All CoC



	0	I	II	III	IV	NA	UNK
My Facility	16.1 % (n=5)	51.6 % (n=16)	22.6 % (n=7)	3.2 % (n=1)	6.5 % (n=2)	0 % (n=0)	0 % (n=0)
All CoC	20.7 % (n=47290)	41.9 % (n=95776)	24 % (n=54796)	7.7 % (n=17723)	3.9 % (n=8942)	0.1 % (n=175)	1.8 % (n=4042)




In/Out Migration Breast Cancer, 2011 - 2013 - My Facility



	2011	2012	2013
Diagnosed Here and Treated Elsewhere	18.8 % (n=6)	0 % (n=0)	3.2 % (n=1)
Diagnosed and Treated Here	81.3 % (n=26)	93.5 % (n=29)	90.3 % (n=28)
Diagnosed Elsewhere and Treated Here	0 % (n=0)	6.5 % (n=2)	6.5 % (n=2)




In/Out Migration by Insurance Status Breast Cancer, 2013 My Facility



	Not Insured	Private/Managed	Medicaid	Medicare	Other Government	Unknown
Diagnosed Here and Treated Elsewhere	0 % (n=0)	0 % (n=0)	0 % (n=0)	3.2 % (n=1)	0 % (n=0)	0 % (n=0)
Diagnosed and Treated Here	6.5 % (n=2)	25.8 % (n=8)	6.5 % (n=2)	51.6 % (n=16)	0 % (n=0)	0 % (n=0)
Diagnosed Elsewhere and Treated Here	0 % (n=0)	0 % (n=0)	3.2 % (n=1)	3.2 % (n=1)	0 % (n=0)	0 % (n=0)

Insurance Status - Breast Cancer, 2010 - 2013


My Facility vs. All CoC



	2010 My Facility	2011 My Facility	2012 My Facility	2013 My Facility	2013 All CoC
Not Insured	0 % (n=0)	6.3 % (n=2)	0 % (n=0)	6.5 % (n=2)	2.3 % (n=5231)
Private/Managed	45.5 % (n=10)	28.1 % (n=9)	29 % (n=9)	25.8 % (n=8)	50.3 % (n=115134)
Medicaid	9.1 % (n=2)	6.3 % (n=2)	9.7 % (n=3)	9.7 % (n=3)	6.5 % (n=14842)
Medicare	45.5 % (n=10)	59.4 % (n=19)	58.1 % (n=18)	58.1 % (n=18)	37.6 % (n=86010)
Other Government	0 % (n=0)	0 % (n=0)	3.2 % (n=1)	0 % (n=0)	1.4 % (n=3223)
Insurance Status Unknown	0 % (n=0)	0 % (n=0)	0 % (n=0)	0 % (n=0)	1.9 % (n=4304)




Distance Traveled - Breast Cancer, 2013



	<5 miles	5-9 miles	10-24 miles	25-49 miles	50-99 miles	>=100 miles	Unknown
My Facility	38.7 % (n=12)	32.3 % (n=10)	29 % (n=9)	0 % (n=0)	0 % (n=0)	0 % (n=0)	0 % (n=0)
All CoC	18.7 % (n=42765)	23.1 % (n=52814)	33 % (n=75525)	13.9 % (n=31710)	5.5 % (n=12638)	2.4 % (n=5487)	0.5 % (n=1069)

First Course Treatment Stage I Breast Cancer, 2013


My Facility vs. All CoC



	Surgery Only	Surgery & Radiation	Surgery & Chemotherapy	Surgery, Radiation & Chemotherapy	Surgery, Radiation & Hormone Therapy	Surgery & Hormone Therapy	Surgery, Radiation, Chemotherapy & Hormone Therapy	Surgery, Chemotherapy & Hormone Therapy	Other Specified Therapy	No 1st Course Rx
My Facility	25 % (n=4)	0 % (n=0)	0 % (n=0)	0 % (n=0)	50 % (n=8)	12.5 % (n=2)	0 % (n=0)	0 % (n=0)	6.3 % (n=1)	6.3 % (n=1)
All CoC	12.9 % (n=12331)	7.3 % (n=6950)	4.2 % (n=4062)	4.4 % (n=4200)	33.6 % (n=32223)	19.1 % (n=18290)	5.2 % (n=4956)	3.1 % (n=3013)	6.2 % (n=5939)	1.8 % (n=1723)




Days to First Treatment Quartiles Breast Cancer: Cases Diagnosed and Treated at My Facility, 2013



	0-16	17-28	29-43	>=44
My Facility	16.7 % (n=4)	37.5 % (n=9)	33.3 % (n=8)	12.5 % (n=3)

Percent for my facility represents what percent of our patients were treated within the number of days in this table. The "national" benchmarks for CoC-accredited programs are represented by the Quartiles represented in the column.

Days to First Treatment Quartiles Breast Cancer: Cases Diagnosed at My Facility or Elsewhere; Treated at My Facility, 2013



	0-16	17-28	29-43	>=44
My Facility	16.7 % (n=4)	37.5 % (n=9)	33.3 % (n=8)	12.5 % (n=3)

Percent for my facility represents what percent of our patients were treated within the number of days in this table. The "national" benchmarks for CoC-accredited programs are represented by the Quartiles represented in the column.



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards. Better Outcomes

100+ years

CQIP

Cancer Quality Improvement Program




© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Colon Cancer—Additional Reports

- Stage Distribution
- In/Out Migration
- In/Out Migration by Insurance Status
- Insurance Status
- Distance Traveled
- Days to First Treatment: Cases Diagnosed and Treated at My Facility
- Days to First Treatment: Cases Diagnosed at My Facility or Elsewhere; Treated at My Facility




Stage Distribution - Colon Cancer Diagnosed in 2013, My Facility vs. All CoC



	0	I	II	III	IV	NA	UNK
My Facility	9.5 % (n=2)	19 % (n=4)	19 % (n=4)	33.3 % (n=7)	9.5 % (n=2)	0 % (n=0)	9.5 % (n=2)
All CoC	5.8 % (n=4165)	19.8 % (n=14305)	24.4 % (n=17615)	24.9 % (n=17946)	20 % (n=14447)	0.1 % (n=91)	4.9 % (n=3510)



In/Out Migration Colon Cancer, 2011 - 2013 - My Facility




	2011	2012	2013
Diagnosed Here and Treated Elsewhere	23.5 % (n=4)	0 % (n=0)	19 % (n=4)
Diagnosed and Treated Here	76.5 % (n=13)	100 % (n=13)	71.4 % (n=15)
Diagnosed Elsewhere and Treated Here	0 % (n=0)	0 % (n=0)	9.5 % (n=2)



In/Out Migration by Insurance Status - Colon Cancer, 2013

My Facility




	Not Insured	Private/Managed	Medicaid	Medicare	Other Government	Unknown
Diagnosed Here and Treated Elsewhere	0 % (n=0)	0 % (n=0)	0 % (n=0)	19 % (n=4)	0 % (n=0)	0 % (n=0)
Diagnosed and Treated Here	9.5 % (n=2)	0 % (n=0)	0 % (n=0)	57.1 % (n=12)	0 % (n=0)	4.8 % (n=1)
Diagnosed Elsewhere and Treated Here	0 % (n=0)	0 % (n=0)	0 % (n=0)	4.8 % (n=1)	0 % (n=0)	4.8 % (n=1)



Insurance Status - Colon Cancer, 2010 - 2013


My Facility vs. All CoC



	2010 My Facility	2011 My Facility	2012 My Facility	2013 My Facility	2013 All CoC
Not Insured	0 % (n=0)	0 % (n=0)	23.1 % (n=3)	9.5 % (n=2)	3.9 % (n=2834)
Private/Managed	12.5 % (n=2)	23.5 % (n=4)	15.4 % (n=2)	0 % (n=0)	31.2 % (n=22513)
Medicaid	6.3 % (n=1)	17.6 % (n=3)	7.7 % (n=1)	0 % (n=0)	5.5 % (n=3933)
Medicare	81.3 % (n=13)	58.8 % (n=10)	53.8 % (n=7)	81 % (n=17)	55.5 % (n=39968)
Other Government	0 % (n=0)	0 % (n=0)	0 % (n=0)	0 % (n=0)	2.2 % (n=1601)
Insurance Status Unknown	0 % (n=0)	0 % (n=0)	0 % (n=0)	9.5 % (n=2)	1.7 % (n=1230)




Distance Traveled - Colon Cancer, 2013



	<5 miles	5-9 miles	10-24 miles	25-49 miles	50-99 miles	>=100 miles	Unknown
My Facility	42.9 % (n=9)	19 % (n=4)	38.1 % (n=8)	0 % (n=0)	0 % (n=0)	0 % (n=0)	0 % (n=0)
All CoC	21.5 % (n=15504)	23.4 % (n=16888)	29.5 % (n=21299)	12.9 % (n=9313)	6.5 % (n=4683)	2.9 % (n=2083)	0.4 % (n=308)

Days to First Treatment Tertiles Colon Cancer: Cases Diagnosed and Treated at My Facility, 2013



	0-1	2-19	>=20
My Facility	41.7 % (n=5)	16.7 % (n=2)	41.7 % (n=5)

Percent for my facility represents what percent of our patients were treated within the number of days in this table. The "national" benchmarks for CoC-accredited programs are represented by the 50th Percentile represented in the column.




Melanoma of the Skin Cancer—Additional Reports

- Stage Distribution
- In/Out Migration
- In/Out Migration by Insurance Status
- Insurance Status
- Distance Traveled
- Days to First Treatment: Cases Diagnosed and Treated at My Facility
- Days to First Treatment: Cases Diagnosed at My Facility or Elsewhere; Treated at My Facility



Stage Distribution - Melanoma Cancer Diagnosed in 2013


My Facility vs. All CoC



	0	I	II	III	IV	NA	UNK
My Facility	42.9 % (n=3)	14.3 % (n=1)	0 % (n=0)	28.6 % (n=2)	0 % (n=0)	0 % (n=0)	14.3 % (n=1)
All CoC	26.9 % (n=14104)	42.4 % (n=22258)	12.6 % (n=6630)	8.5 % (n=4466)	4.4 % (n=2336)	0 % (n=2)	5.2 % (n=2715)




In/Out Migration Melanoma Cancer, 2011 - 2013 - My Facility



	2011	2012	2013
Diagnosed Here and Treated Elsewhere	25 % (n=1)	0 % (n=0)	0 % (n=0)
Diagnosed and Treated Here	25 % (n=1)	100 % (n=4)	57.1 % (n=4)
Diagnosed Elsewhere and Treated Here	50 % (n=2)	0 % (n=0)	42.9 % (n=3)




In/Out Migration by Insurance Status Melanoma Cancer, 2013 My Facility



	Not Insured	Private/Managed	Medicaid	Medicare	Other Government	Unknown
Diagnosed Here and Treated Elsewhere	0 % (n=0)	0 % (n=0)	0 % (n=0)	0 % (n=0)	0 % (n=0)	0 % (n=0)
Diagnosed and Treated Here	14.3 % (n=1)	0 % (n=0)	0 % (n=0)	42.9 % (n=3)	0 % (n=0)	0 % (n=0)
Diagnosed Elsewhere and Treated Here	0 % (n=0)	0 % (n=0)	0 % (n=0)	42.9 % (n=3)	0 % (n=0)	0 % (n=0)




Insurance Status - Melanoma Cancer, 2010 - 2013 My Facility vs. All CoC



	2010 My Facility	2011 My Facility	2012 My Facility	2013 My Facility	2013 All CoC
Not Insured	14.3 % (n=1)	0 % (n=0)	0 % (n=0)	14.3 % (n=1)	2.4 % (n=1235)
Private/ Managed	57.1 % (n=4)	0 % (n=0)	25 % (n=1)	0 % (n=0)	47.3 % (n=24822)
Medicaid	0 % (n=0)				
Medicare	28.6 % (n=2)	100 % (n=4)	75 % (n=3)	85.7 % (n=6)	42.6 % (n=22374)
Other Government	0 % (n=0)				
Insurance Status Unknown	0 % (n=0)				




Distance Traveled - Melanoma Cancer, 2013 - My Facility



	<5 miles	5-9 miles	10-24 miles	25-49 miles	50-99 miles	>=100 miles	Unknown
My Facility	71.4 % (n=5)	0 % (n=0)	28.6 % (n=2)	0 % (n=0)	0 % (n=0)	0 % (n=0)	0 % (n=0)
All CoC	11.9 % (n=6235)	16.8 % (n=8843)	31.3 % (n=16410)	19.1 % (n=10013)	11 % (n=5786)	5.8 % (n=3054)	0.3 % (n=167)

Days to First Treatment 90th Percentile Melanoma Cancer: Cases Diagnosed and Treated at My Facility, 2013




	0-39	≥40
My Facility	66.7 % (n=2)	33.3 % (n=1)

Percent for my facility represents what percent of our patients were treated within the number of days in this table. The "national" benchmarks for CoC-accredited programs are represented by the 90th Percentile represented in the column.



Days to First Treatment 90th Percentile Melanoma Cancer: Cases Diagnosed at My Facility or Elsewhere; Treated at My Facility, 2013



	0-39	>=40
My Facility	66.7 % (n=2)	33.3 % (n=1)

Percent for my facility represents what percent of our patients were treated within the number of days in this table. The "national" benchmarks for CoC-accredited programs are represented by the 90th Percentile represented in the column.



Commission on Cancer

- Established by the American College of Surgeons (ACoS) in 1922
- A consortium of professional organizations dedicated to improving survival and quality of life for cancer patients
- Sets standards to ensure quality, multidisciplinary, and comprehensive cancer care delivery in health care settings
- Conducts surveys to assess compliance with those standards
- Collects standardized data to measure cancer care quality
- Uses data to monitor treatment patterns and outcomes and enhance cancer control and clinical surveillance activities
- Develops educational interventions to improve cancer prevention, early detection, cancer-care delivery, and outcomes




Commission on Cancer: The Value of Accreditation

- **Demonstrates commitment** to patients, communities, providers, payers, and policymakers to improving survival and quality of life for patients and to evidence-based, organized, comprehensive, and quality cancer care
- **Standards ensure that state-of-the-art** clinical services for diagnosing, treating, rehabilitating, and supporting cancer patients and their families are available to provide **quality care**
- **National Cancer Data Base** participation by cancer registries captures more than 100 data elements for every patient and more than 70% of all new cancer patients diagnosed in the U.S. each year. Participant User File (PUF) access for research is only available to investigators at CoC-approved programs
- **Measuring quality and outcomes**, including overall survival, through a rapidly expanding panel of quality measures for cancers of the breast, colon, rectum, lung, esophagus, and stomach, and soon to include gynecologic and urologic malignancies, melanoma, sarcoma and pediatric tumors. Comparison with nation-wide data from all 1,500 CoC-accredited programs
- **Ensures a multidisciplinary team approach** including information and access to clinical trials, access to prevention and early detection programs, cancer conferences, and oversight by a Cancer Committee



Commission on Cancer - Accredited Programs By State



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality:
Highest Standards, Better Outcomes

100+ years

CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Role of the Cancer Liaison Physician (CLP)

CLPs monitor the performance of their Cancer Program to address challenges and opportunities using information from the following NCDB Tools that include:

Accountability Measures
Quality Improvement Measures
Surveillance Measures
Survival Reports

Cancer Program Profile Practice Reports (CP3R)
Cancer Quality Improvement Program (CQIP)
Hospital Comparison Benchmark Reports (HCBM)
Rapid Quality Reporting System (RQRS)

***Standard 4.3** Role of the Cancer Liaison Physician - A Cancer Liaison Physician serves in a leadership role within the cancer program, and is responsible for evaluating, interpreting and reporting the program's performance using the National Cancer Data Base (NCDB) data. The CLP reports the results of this analysis to the cancer committee at least four times a year.*

CQIP – A Resource for the Cancer Liaison Physician Reporting to Cancer Committee



Commission on Cancer Member Organizations

- Academy of Nutrition and Dietetics (AND)
- Academy of Oncology Nurse and Patient Navigators (AONN+)
- Alliance for Clinical Trials in Oncology (ALLIANCE)
- American Academy of Hospice and Palliative Medicine (AAHPM)
- American Academy of Pediatrics (AAP)
- American Association for Cancer Education (AACE)
- American Cancer Society (ACS)
- American College of Obstetricians and Gynecologists (ACOG)
- American College of Physicians (ACP)
- American College of Radiology (ACR)
- American College of Surgeons Resident and Associate Society (ACOSRAS)
- American College of Surgeons Young Fellows Association (ACOSYFA)
- American Head and Neck Society (AHNS)
- American Hospital Association (AHA)
- American Joint Committee on Cancer (AJCC)
- American Medical Association (AMA)
- American Pediatric Surgical Association (APSA)
- American Physical Therapy Association (APTA)
- American Psychosocial Oncology Society (APOS)
- American Radium Society (ARS)
- American Society of Breast Surgeons (ASBS)
- American Society of Clinical Oncology (ASCO)
- American Society of Colon and Rectal Surgeons (ASCRS)
- American Society of Plastic Surgeons (ASPS)
- American Society of Radiation Oncology (ASTRO)
- American Urological Association (AUA)
- Association of American Cancer Institutes (AACI)
- Association of Cancer Executives (ACE)
- Association of Community Cancer Centers (ACCC)
- Association of Oncology Social Work (AOSW)
- Cancer Support Community (CSC)
- Centers for Disease Control and Prevention (CDC)
- College of American Pathologists (CAP)
- Community Oncology Alliance (COA)
- Department of Defense (DOD)
- Department of Veterans Affairs (VA)
- Hematology/Oncology Pharmacy Association (HOPA)
- LIVESTRONG (Lance Armstrong Foundation)
- National Accreditation Program for Breast Centers (NAPBC)
- National Cancer Institute (NCI)
 - Applied Research Program
 - SEER Program
- National Cancer Registrars Association (NCRA)
- National Coalition for Cancer Survivorship (NCCS)
- National Comprehensive Cancer Network (NCCN)
- National Consortium of Breast Centers (NCBC)
- National Society of Genetic Counselors (NSGC)
- National Surgical Adjuvant Breast and Bowel Project (NSABP)
- North American Association of Central Cancer Registries (NAACCR)
- Oncology Nursing Society (ONS)
- Society of Gynecologic Oncology (SGO)
- Society for Immunotherapy of Cancer (SITC)
- Society of Nuclear Medicine and Molecular Imaging (SNMMI)
- Society of Surgical Oncology (SSO)
- Society of Thoracic Surgeons (STS)



National Cancer Data Base (NCDB)

- A joint program of the CoC and the American Cancer Society that began in 1988
- A nationwide oncology database for more than 1,500 CoC-accredited U.S. cancer programs
- 70 percent of all newly diagnosed U.S. cancer cases are captured at the facility level and reported
- Contains approximately 32 million records from hospital cancer registries across the U.S.



American College of Surgeons: 100 Years of Quality Improvement



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality:
Highest Standards, Better Outcomes

100-years

CQIP


Cancer Quality Improvement Program



© American College of Surgeons 2015—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

The American College of Surgeons and The American Cancer Society

Partners to Improve the Lives of Cancer Patients



The Commission on Cancer acknowledges the support of the American Cancer Society for their support of the National Cancer Data Base and the Cancer Liaison Physician Program



Acknowledgements

American College of Surgeons Commission on Cancer

Daniel P. McKellar, MD, FACS, Chair
David P. Winchester, MD, FACS, Medical Director, Cancer Programs
Ryan McCabe Ph.D Senior Manager, National Cancer Database

Commission on Cancer Committee Leadership 2014 - 2015

Accreditation

Linda W. Ferris PhD, Chair
Danny Takanishi, MD, FACS, Vice-Chair

Cancer Liaison

Philip Y. Roland, MD, FACS, FACOG, Chair
Mary J. Milroy, MD, FACS, Vice-Chair

Education

Howard L. Kaufman, MD, FACS, Chair
Hisakasu Hoshi, MD, FACS, Vice-Chair

Member Organizations

Carma Herring, RN, OCN, Chair
Peter T. Hetzler, MD, FACS, Vice-Chair

Quality Integration

Lawrence N. Shulman, MD,, FACP Chair
Ned Carp, MD, FACS Vice-Chair

CQIP

Lawrence N. Shulman, MD, CQIP Project Director
Kenneth Pristas, CQIP Project Manager, MSHI, PMP

CQIP/NCDB Staff

Greer Gay, Ph.D, RN
Natalie Goodwin, MS
Dennis Harman, MS
Ashley Loomis, MPH
Katherine Mallin, Ph.D
Bryan Palis, MA
Florin Petrescu, MS
Kenneth Pristas, MSHI, PMP

Further Assistance

Kenneth Pristas, MSHI, PMP
NCDB IT Manager
Phone: 312-202-5451
Email: kpristas@facs.org

CQIP Email

ncdbcqip@facs.org





AMERICAN COLLEGE OF SURGEONS

*Inspiring Quality:
Highest Standards, Better Outcomes*

100+years

CQIP

Cancer Quality Improvement Program



Commission
on Cancer®

CQIP

Cancer Quality Improvement Program

Commission on Cancer

www.facs.org/quality-programs/cancer/coc

312-202-5085

CQIP

www.facs.org/quality-programs/cancer/ncdb/qualitytools/cqip